{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Oramed Pharmaceuticals Issues Letter to Shareholders - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"tGYCc39AvH\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oramed-pharmaceuticals-issues-letter-to-shareholders\/\">Oramed Pharmaceuticals Issues Letter to Shareholders<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/oramed-pharmaceuticals-issues-letter-to-shareholders\/embed\/#?secret=tGYCc39AvH\" width=\"600\" height=\"338\" title=\"&#8220;Oramed Pharmaceuticals Issues Letter to Shareholders&#8221; &#8212; Market Newsdesk\" data-secret=\"tGYCc39AvH\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"PR Newswire Key Highlights \u2013 expected completion in YR 2025: OraTech Pharmaceuticals Inc. &#8211; A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials. Distribution of majority of Oramed&#8217;s holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech&#8217;s public listing. Cash dividend planned (~$0.25 per share). Marketing Authorization Application has been submitted by HTIT, and commercialization preparations are underway for oral insulin capsule. OraTech expected to receive royalties from sales in China. Oramed to receive royalty streams over the next decade from multiple Scilex products including $400,000 due for Q4 2024 sales. NEW YORK , March 4, 2025 \/PRNewswire\/ &#8212; Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (&#8220;Oramed&#8221;), a clinical-stage pharmaceutical &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/mma.prnewswire.com\/media\/1724339\/Oramed_Logo.jpg"}